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The Catalogue Of Somatic Mutations In Cancer (COSMIC) database and web site was developed to preserve somatic mutation data
and share it with the community. Over the past 25 years, approximately 350 cancer genes have been identified, of which 311 are
somatically mutated. COSMIC has been expanded and now holds data previously reported in the scientific literature for 28 known
cancer genes. In addition, there is data from the systematic sequencing of 518 protein kinase genes. The total gene count in COSMIC
stands at 538; 25 have a mutation frequency above 5% in one or more tumour type, no mutations were found in 333 genes and 180
are rarely mutated with frequencies o5% in any tumour set. The COSMIC web site has been expanded to give more views and
summaries of the data and provide faster query routes and downloads. In addition, there is a new section describing mutations found
through a screen of known cancer genes in 728 cancer cell lines including the NCI-60 set of cancer cell lines.
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All cancers arise through the acquisition of a number of DNA
sequence mutations, some of which confer growth advantage and
drive the clonal expansion of the tumour cells (Vogelstein and
Kinzler, 1998). At the DNA sequence level the mutations include
base substitutions, deletions, amplifications and rearrangements. It
is likely that many somatic mutations are a consequence of defects
in DNA repair and maintenance (Slupphaug et al, 2003; Barnes and
Lindahl, 2005) or past exposure to mutagens (Luch, 2005) or both
of these phenomena. Are all somatic mutations critical for the
development of the tumour in which they are found? Probably not,
but the proportion of mutations that are causally implicated in
cancer is unclear and certainly varies from tumour to tumour
(Wang et al, 2004; Davies et al, 2005; Stephens et al, 2005; Bignell
et al, 2005). Differentiating passenger events from disease causing
mutations is a challenge, particularly for genes that are infre-
quently mutated or have silent or noncoding mutations. This
contrasts with genes that are frequently mutated, beyond what
would be expected by chance, or have mutations that cluster in key
amino-acid residues or functional protein domains. In these cases
the genetic evidence on its own strongly implies these genes are
involved in the development of cancer. What is clear is the utility
of mutation data.
The small intragenic mutation data that defines known cancer
genes is buried in the scientific literature. There are extensive
databases and web sites that actively curate the literature for
germline mutations in cancer genes, for example HGVbase
(Fredman et al, 2002) and the Human Gene Mutation Database
(HGMD, Stenson et al, 2003). In addition, there are many
databases that store and serve somatic mutation data for single
genes (see http://www.hgvs.org for an extensive list). Some of these
are actively maintained, such as those for TP53 (Olivier et al, 2002;
Be ´roud and Soussi, 2003), however, most are not updated.
Furthermore, there is wide variation in the data that is stored,
the extent of queries that can be levelled at the data and the ability
to display and download the results. Although all these resources
have value they are dispersed across the internet and thus it is
difficult to make direct comparisons between cancer genes.
Since the early days of sequencing genes in tumours there have
been reports of infrequently mutated genes and occasionally
genes that appear to have no mutations. This data is now joined by
the results of the systematic sequencing of genes in tumours
(Bardelli et al, 2003; Wang et al, 2004; Davies et al, 2005; Bignell
et al, 2005; Stephens et al, 2005) that also report infrequently
mutated genes and many more genes with no mutations. Is this
data worth preserving? Definitely yes, both to disseminate the
mutation data to a wide audience and as a means of preserving the
negative data.
The Catalogue of Somatic Mutations in Cancer, COSMIC,
(http://www.sanger.ac.uk/cosmic) was launched in 2004 as a free
resource to hold and display somatic mutation data for four genes;
BRAF, HRAS, KRAS and NRAS (Bamford et al, 2004). The data in
COSMIC has expanded to include data on 538 genes, 124367
tumours with 23157 mutations. The web site has been expanded to
provide summary pages for the genes, tissue types, references,
samples and mutations. In addition, there are new sections
detailing the results of our sequencing of known cancer genes in
728 publicly available cancer cell lines that incorporate the NCI-60
cancer cell lines including loss of heterozygosity data and copy
number information for many of these cancer cell lines.
DATA CURATION
The genes that have been selected for curation are a subset
from the Cancer Gene Census (http://www.sanger.ac.uk/CGP/
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sCensus Futreal et al, 2004) and other genes that have been
screened for somatic mutations with either negative or incon-
clusive results. The data held in COSMIC is extracted from the
literature as described in Bamford et al, 2004. Once a gene is
included in COSMIC there is an ongoing process to curate
additional data after it is published. There is usually a delay
between publication of data and its appearance in COSMIC while
the data is curated.
To enhance the utility of COSMIC we standardise the curated
data. We extract the tissue and histology for each sample
and map the definitions to the COSMIC classification tables
(see http://www.sanger.ac.uk/genetics/CGP/cosmic/data/cosmic_
classification_alias_list_01_11_05.xls). This yields a standard set
of tumour descriptions that can be queried through the web site.
The original definition is always maintained in the database.
In a similar fashion, a single DNA sequence is held for each
transcript. The transcript sequence is translated to give the
protein sequence used by COSMIC. This information is
available for each gene and all mutations are mapped to
these standard sequences. For example, all BRAF V599E
mutations are remapped to amino acid 600 in the COSMIC
BRAF protein sequence (see Davison et al, 2005 for a typical
example).
Potential data biases
The data held in COSMIC that is extracted from the literature is
likely to have a number of biases. There is potential for publication
prejudice where positive data is more likely to appear in print than
negative data. There are almost certainly biases in the samples that
have been analysed as many studies are performed using tumours
from Europe and the USA. Where particular patient groups appear
interesting there is often a surge of analysis that can distort the
mutation landscape, for instance the reported population bias in
EGFR mutations (Paez et al, 2004). Furthermore, it is a common
practice to screen mutation hotspots in known cancer genes, for
example, the selective analysis of codons 12 and 13 in the RAS
genes. Where possible all data is entered in to COSMIC rather than
selecting specific data sets. When viewing the data in COSMIC
there is always a link to the publications that were curated making
it possible to view the original data, samples and methods to
understand any biases.
DATABASE
The COSMIC database is implemented in Oracle. The schema has
expanded since the launch of COSMIC to encompass additional
Figure 1 Tissue overview. The mutation data for a selected tissue is presented in a summary format, in this case for prostate. The top 5 genes with data in
COSMIC are selected as the genes with the highest rank score using the method; RankScore¼number of mutations/number of samples –
1.6449 squareroot((number of mutations/number of samples) (1–(number of mutations/number of samples)/number of samples). The data is
presented in both graphical and tabular formats. Further genes with and without mutations for the selected tissue are listed. All of the gene names can be
followed to view the details of the mutations.
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Supplementary data).
The main development of the database has been the introduc-
tion of feature tables that are linked to the individual and
tumour tables. The feature tables are a generic approach to storing
any information relating to the individual and tumour. The
features are grouped into feature types, for example, ethnicity.
Any ethnic name can be added to this feature type. A more
complex feature type is cigarette smoking history. The values that
have been stored so far for this feature type include values
expressed as pack years as well as less specific comments, such as
smoker, nonsmoker, ex-smoker and never-smoker. This system
allows COSMIC to capture the wide range of information reported
in the literature. It also accepts different data content for different
genes, for example, drug response information for tumours with
and without EGFR mutations. The other noteworthy addition to
the COSMIC schema is a pair of tables that store external data
sources for the samples held in COSMIC (see Other Data Types
below).
WEB SITE
The COSMIC web site has been further developed to provide faster
access to the data, new views and summaries and new links to aid
navigation around the various pages.
There are two routes to the data; selecting a gene or a tissue. The
gene selection is either alphabetical or by chromosome position.
There are two tissue selection paths. The Browse by Tissue route
presents a list of tissues, subtissues then histologies and
subhistologies, which culminate in a tissue overview display
(Figure 1). The Quick Tissue path proceeds straight from the tissue
selection to the overview page.
The gene summary page provides an overview of the data for
each gene (Figure 2). The position of recorded mutations is shown
on an overview of the protein sequence with links to the gene
histogram page. In addition the gene summary has links to
external data sources for the gene, the references that have been
curated and an overall sample and mutation count. The gene
histogram page has been developed from the original web site to
Figure 2 Gene summary. The initial output for a gene is a graphical view of the mutations distributed along the linear amino acid sequence of the gene.
This is the data for RB1. The positions of the mutations are shown by tick marks with tracks showing the total number of mutations and mutations that are
insertions, nonsense substitutions, missense substitutions, deletions and complex substitutions. In addition the summary presents the number of references
curated, the number of samples for the gene and the number of samples with mutations. There are multiple links from this view leading to web pages
describing more details of the mutations, the gene and the references that have been curated.
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still shows the mutation position, frequency data by tumour type
and details of the mutations (not shown). The gene histogram
display now also maps the positions of insertions, deletions and
complex mutations. The reference summary page presents a list of
the genes that were screened in each paper, the samples that had
mutations with details of the mutation and the names of the
samples that had no mutations in the genes that were screened
(not shown). The details for each of the samples and each mutation
are presented in two separate summary pages (not shown).
MUTATION CONTENT
The genes in COSMIC can be split into three categories. In all, 28
genes in COSMIC are considered as causal cancer genes in the
Cancer Gene Census where the genetic and biological data (where
available) indicates that mutations in the genes are almost
certainly involved in the development of cancer (Table 1). Of
these, 25 have a mutation frequency above 5% in one or more
tumour type while the other three, ERBB2, FGFR2 and SUFU, have
biologically plausible mutations but a low mutation frequency
(mutation frequencies in all available data are; 1.2% for ERBB2, 2%
for FGFR2 and 1.6% for SUFU). On the COSMIC web site these
genes are grouped in the gene selection page. The data is current
for all of the genes except TP53. The results for TP53 are essentially
additional information from other work. They have been included
in COSMIC but do not constitute a comprehensive survey of TP53
mutation data. Other resources such as the IARC TP53 database
(Olivier et al, 2002) give a far more extensive set of TP53 data.
The second set of genes in COSMIC have somatic mutations in
cancers, however the frequency of mutations is low, generally
o5% in all tumour types, and/or they are not located in known
functionally significant positions in the proteins. This set
comprises 180 genes. The majority of these genes have been
screened in a small number of samples. However, a small subset,
for example, ACVR1B and CSF1R, have been screened in many
cancers. The role of these mutated genes in the development of
cancer is unclear and the mutations could be termed ‘somatic
variants of unknown significance’. In all likelihood most are not
causally implicated in oncogenesis, that is, the mutations are
passenger (also known as bystander) mutations. However, it is
equally plausible that a minority is involved in cancer develop-
ment, although it is currently not possible to determine which.
The final set of genes has been screened for mutations but none
have been reported. This set of genes is large (333) with the data
coming from the sequencing of all 518 protein kinase genes in: 25
breast cancers (Stephens et al, 2005), 33 lung cancers (Davies et al,
2005) and 13 testicular germ cell tumours (Bignell et al, 2005). In
general, this type of data is either not present in the literature or
the description is cursory making it difficult to enter in COSMIC. If
mutations are found in these genes in the future, the status of the
genes in COSMIC would be modified.
CANCER CELL LINES AND KNOWN CANCER GENES
Cancer cell lines have been used extensively in the biological
characterisation of cancer and in the analysis of both novel and
routinely used anticancer drugs. On the whole this has taken place
with little or no consideration of the DNA sequence of known
cancer genes in these samples. To redress this imbalance COSMIC
now displays mutation data that we have generated from known
cancer genes in the NCI-60 cell line panel of 59 lines and a further
669 cancer cell lines (http://www.sanger.ac.uk/genetics/CGP/
CellLines/). Some of these cell lines have been sequenced in the
past. For example, TP53 has been sequenced in the NCI-60
(O’Connor et al, 1997) while other lines have been used as positive
controls in mutation screening experiments. Rather than curate
this rather piecemeal set of results, we have begun to systematically
resequence known cancer genes in this group of cell lines.
OTHER DATA TYPES
There is additional genetic data for the samples being analysed by
us (http://www.sanger.ac.uk/genetics/CGP). In all, 829 cancer cell
lines in COSMIC have loss of heterozygosity maps produced
by genotyping 395 polymorphic CA repeats from across the
genome. The samples analysed in the protein kinase mutation
screen (http://www.sanger.ac.uk/genetics/CGP/Kinases) and normal
samples from the same individuals have been genotyped with
the Affymetrix 10k SNP array. This data has also been used to
calculate loss of heterozygosity maps. In addition, the intensity
data from the SNP arrays has been used to generate chromosome
copy number maps. The SNP and CA repeat data is integrated with
the mutation data to provide a wider genetic perspective of these
samples.
FUTURE DIRECTIONS
The publication of data from systematic mutation screens provides
a new avenue for COSMIC. The volume of systematic data is likely
to grow and provide a wider insight into the mutation burden in
cancer. The screening of known cancer genes in cancer cell lines
provides a resource to both the genetics community and those
Table 1 Mutation statistics for the known cancer genes curated in
COSMIC
Gene References
Unique
mutations
Samples
with
mutations
Samples
without
mutations
ABL1 18 52 172 552
BRAF 144 77 2767 11509
CEBPA 1 10 10 127
CTNNB1 240 261 1466 10643
EGFR 39 139 685 5398
ERBB2 8 12 20 1693
FGFR2 5 6 5 237
FGFR3 29 21 484 1507
FLT3 50 46 1493 5859
GATA1 4 10 15 69
HRAS 251 28 472 11462
JAK2 9 1 473 568
KIT 113 247 768 2421
KRAS 749 60 8402 29328
MET 29 29 66 1503
MSH6 11 18 89 588
NOTCH1 1 64 72 48
NRAS 313 33 1110 13378
PDGFRA 17 35 207 1060
PIK3CA 9 62 310 1988
PTEN 180 678 1243 7830
PTPN11 9 43 110 2268
RB1 59 126 168 1330
RET 48 35 218 1097
SMARCB1 21 78 193 1348
SMO 7 17 25 234
SUFU 3 4 4 240
TP53 3 9 10 61
Totals 2370 2201 21057 114346
The data for TP53 is not a comprehensive review of the literature for this gene. Some
of the samples screened for mutations in other genes were incidentally screened
through TP53 and this data has been captured.
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this data further.
The value of small intragenic mutation data can be enhanced by
integrating other data types. As a first step, we have integrated
genotyping and copy number data. In the future, we hope to
incorporate other somatic mutation data to further expand the
content of COSMIC. In the meantime, there are plans for the
continued curation of the cancer mutation literature to expand the
number of known cancer genes.
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